Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-06, Vol.386 (25), p.2399-2411
Hauptverfasser:	Foà, Robin, Chiaretti, Sabina
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Age Chemotherapy Chromosomes Clinical trials Disease prevention Glucocorticoids Hematology Immune system Laboratories Leukemia Lymphocytes Lymphoma Monoclonal antibodies Mutation Nervous system Oncology Philadelphia chromosome Protein-tyrosine kinase Remission (Medicine) Targeted cancer therapy Transplants & implants Treatments in Oncology Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMra2113347